U.S. Markets closed

Cellect Biotechnology Ltd. (APOP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8600+0.0600 (+2.14%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8000
Open2.9200
Bid2.8500 x 900
Ask2.9200 x 1400
Day's Range2.5700 - 3.0673
52 Week Range0.4000 - 5.4000
Volume254,075
Avg. Volume255,659
Market Cap11.181M
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-0.8540
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021
    GlobeNewswire

    Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

    Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger AgreementsTEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subsequent to the end of the third quarter, the Company announced several other key achievements subsequent to the end of the third quarter that position it for continued success in 2021, including clinical and operational objectives: * Initiated its clinical trial in the U.S. The trial is being performed at Washington University School of Medicine in St. Louis, Missouri, which is among the leading medical centers in the U.S. The Principal Investigator for the clinical trial is Zhifu Xiang, M.D., of Washington University. He is an Associate Professor in the Division of Oncology's Bone Marrow Transplantation & Leukemia Section in the Department of Medicine. John Dipersio M.D, Ph.D., will act as co-Principal Investigator for the study. He is the chief of the Division of Oncology in the Department of Medicine at Washington University. * Entered into a collaborative agreement with the Swedish XNK Therapeutics, enabling it to leverage Cellect’s technology in Natural Killer cell therapies. XNK is a clinical stage Swedish company working with the Karolinska Institute.“In spite of the COVID-19 challenges we expedited our clinical and business development activities as we successfully achieved several objectives,” commented Dr. Shai Yarkoni, Chief Executive Officer. “Specifically, we recently initiated our U.S. clinical trial and entered into a partnership with a clinical stage biotech company that will leverage our functional cell selection technology. I believe these results reflect our steadfast determination and success progressing our clinical trials, which also includes the trial in Israel, combined with the latest collaboration agreement with XNK Therapeutics gives us multiple shots on goal to maximize shareholder value. We believe, based on our internal evaluation and assessment, that each of these opportunities could potentially represent significant revenue streams in the coming years.”Separately, Cellect and Canndoc Ltd. have mutually agreed to end previously announced commercial and merger discussions. The Company will continue to pursue a partner that can bring value to its shareholders and progress the development of the Company’s platform technology.The Company's cash and cash equivalents totaled $6.07 million as of September 30, 2020. The Company will use its resources to progress clinical and business development efforts to advance its functional cell selection technology. The Company has sufficient funds to operate in the next 15 months. Reference is made to Note 1. C (Going Concern) in the Interim Consolidated Financial Statements as of June 30th, 2020, which were filed as an exhibit to a Form 6-K dated August 12, 2020.Third Quarter 2020 Financial Results: * Research and development (R&D) expenses for the third quarter of 2020 were $0.37 million, compared to $0.72 million in the third quarter of 2019. The decrease in the R&D expenses is primarily due to decrease in clinical activities as a result of the COVID-19. * General and administrative (G&A) expenses for the third quarter of 2020 were $0.36 million compared to $0.80 million in the third quarter of 2019. The decrease in G&A expenses was primarily due to the decrease in professional expenses. * Finance income for the third quarter of 2020 were $0.26 million, compared to finance income of $0.12 million in the third quarter of 2019. The change was primarily due to changes related to the fair value of the tradable and non-tradable warrants issued in a prior fundraising. * Net loss for the third quarter of 2020 was $0.47 million, or $0.001 per share compared to $1.40 million, or $0.006 per share in the third quarter of 2019.* For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on September 30, 2020 (U.S. $1 = NIS 3.441).About Cellect Biotechnology Ltd.Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of cell based therapies.The Company's technology is expected to provide researchers, clinical community, and pharma companies with the tools to rapidly isolate specific cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.Forward Looking Statements         This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company’s ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC.Contact Cellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officer www.cellect.co  +972-9-974-1444OrEVC Group LLC Michael Polyviou (732) 933-2754 mpolyviou@evcgroup.com Cellect Biotechnology Ltd Consolidated Statement of Operation  Convenience           translation           Nine months ended Nine months ended Three months ended   September 30, September 30, September 30,   2020 2020 2019 2020 2019         Unaudited Unaudited   U.S. dollars NIS       (In thousands, except share and per share data)             Research and development expenses 1,218 4,190 9,551 1,289 2,465             General and administrative expenses 1,727 5,944 7,832 1,241 2,768             Operating loss 2,945 10,134 17,383 2,530 5,233             Financial expenses (income) due to warrants exercisable into shares 790 2,717 (8,020) (1,090) (910)             Other financial expenses, net 40 138 1,369 193 489             Total comprehensive loss 3,775   12,989 10,732 1,633 4,812             Loss per share:                       Basic and diluted loss per share 0.010 0.036 0.051 0.004 0.021             Weighted average number of shares outstanding used to compute basic and diluted loss per share 390,949,079 390,949,079 208,771,303 390,949,079 224,087,799 Cellect Biotechnology Ltd. Consolidated Balance Sheet Data Convenience       translation       September 30, September 30, December 31,   2020  2020  2019  Unaudited Unaudited Audited  U.S. dollars NIS  (In thousands, except share and per share data) CURRENT ASSETS:      Cash and cash equivalents6,071  20,889  18,106  Other receivables205  707  469   6,276  21,596  18,575  NON-CURRENT ASSETS:      Restricted cash96  329  328  Right-of-use assets238  819  1,035  Other long-term receivables19  66  94  Property, plant and equipment, net379  1,304  1,288   732  2,518  2,745          7,008  24,114  21,320    CURRENT LIABILITIES:      Trade payables71  243  158  Other payables579  1,994  3,080  Current maturities of lease liability136  468  396   786  2,705  3,634  NON-CURRENT LIABILITIES:      Warrants to ADS354  1,218  2,172  Lease liability112  386  677   466  1,604  2,849  EQUITY:      Ordinary shares of no par value:       Authorized: 500,000,000 shares at December 31, 2019 and September 30, 2020; Issued and outstanding: 390,949,079*) and 224,087,799*) shares as of December 31, 2019 and September 30, 2020, respectively.-  -  -  Additional Paid in Capital36,861  126,839  108,598  Share-based payments4,721  16,244  16,528  Treasury shares(2,739) (9,425) (9,425) Accumulated deficit(33,087) (113,853) (100,864)  5,756  19,805  14,837          7,008  24,114  21,320  *)    Net of 2,641,693 treasury shares of the Company held by the Company. Cellect Biotechnology Ltd Consolidated Cash Flow Data Convenience          translation          Nine months endedNine months ended Three months ended  September 30,September 30, September 30,  2020 2020  2019  2020  2019      UnauditedUnaudited  U.S. dollarsNIS  (In thousands) Cash flows from operating activities:         Total comprehensive loss(3,775)(12,989) (10,732) (1,633) (4,812)           Adjustments to reconcile net loss to net cash used in operating activities:         Exchange rate difference(61)(211) -  (216) -  Net financing expenses14 48  1,087  11  272  Loss (gain) from revaluation of financial assets presented at fair value through profit and loss- -  8  -  2  Depreciation75 256  285  86  93  Changes in fair value of traded and not traded warrants790 2,718  (9,351) (1,089) (910) Share-based payment138 476  1,901  (353) 1,371  Decrease (increase) in other receivables(61)(210) 146  263  -  Decrease in other payables(334)(1,149) (1,855) (396) (1,138) Depreciation of Right of use - Assets under operating lease79 272  457  89  143  Interest received during the period16 56  (75) 21  (29) Net cash used in operating activities(3,119)(10,733) (18,129) (3,217) (5,008)           Cash flows from investing activities:         Restricted deposit, net- (1) -  1  -  Sales (Purchase) of property, plant, and equipment(36)(124) (120) (155) -  Net cash provided by investing activities(36)(125) (120) (154) -            Cash flows from financing activities:         Exercise of warrants and stock options into shares1,341 4,615  -  (92) -  Leases liabilities(94)(324) (422) (112) (143) Issue of share capital and warrants, net of issue costs2,672 9,194  23,723  -  -  Net cash provided (used) by financing activities3,919 13,485  23,301  (204) (143) Exchange differences on balances of cash and cash equivalents45 156  (1,012) 195  (243) Increase (decrease) in cash and cash equivalents809 2,783  4,040  (3,380) (5,394) Balance of cash and cash equivalents at the beginning of the period5,262 18,106  17,809  24,269  27,243  Balance of cash and cash equivalents at the end of the period6,071 20,889  21,849  20,889  21,849

  • Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology
    GlobeNewswire

    Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology

    Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therapies. 

  • Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
    GlobeNewswire

    Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft

    Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that it has initiated its clinical trial in the U.S. to determine the safety and tolerability of the ApoGraft technology for bone marrow transplantations (BMT).  The trial will enroll 18 patients and the primary end point of the study is overall incidence, frequency and severity of adverse events potentially related to ApoGraft at 180 and 360 days from transplantation.This is the second clinical trial of ApoGraft.  The first trial in Israel has enrolled eleven patients, and the dose level of the final cohort is identical to the dose level used in the U.S. trial. The Company has previously disclosed interim data showing that the trial unequivocally met the safety and tolerability end point, and the Company expects to publish top line data in early 2021.“This is a pivotal development for Cellect, and it demonstrates a significant step forward as we embark on our first-ever U.S. clinical trial for ApoGraft,” commented Dr. Shai Yarkoni, Chief Executive Officer.  “Although the COVID-19 pandemic impacted our expected commencement and timelines, I am encouraged by the work of our team and collaborators as they navigated all the pandemic constraints after the U.S. Investigational New Drug (IND) approval. We plan to leverage our collaborators’ support and expertise to seek out further indications and regulatory approvals for other indications of cell therapy where ApoGraft may be used. This is an exciting period for Cellect, and we are pleased to begin treating patients in this trial in the coming weeks.”The trial will be conducted by bone marrow transplantation specialists at Washington University School of Medicine, a leading academic institution based in St. Louis, Missouri and is co-sponsored by the university and Cellect.   ApoGraft cell selection technology is designed to prevent graft-versus-host disease (GVHD) following bone marrow transplantation. This is an open label phase 1 clinical trial of eighteen patients and is designed to evaluate the safety and tolerability of the ApoGraft process in patients with hematological malignancies who are undergoing a haploidentical hematopoietic stem cell transplantation (HSCT). The Principal Investigator for the clinical trial is Zhifu Xiang, M.D., of Washington University. He is an Associate Professor in the Division of Oncology's Bone Marrow Transplantation & Leukemia Section in the Department of Medicine. In addition, Mark Schroeder, M.D., and John DiPersio M.D., Ph.D., will act as co-Principal Investigators for the study. Dr. DiPersio is the chief of the Division of Oncology in the Department of Medicine at Washington University. The collaboration is led by Dr. DiPersio, who also is Director of the Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, and a past president of the American Society for Blood and Marrow Transplantation. About Cellect Biotechnology Ltd.Cellect Biotechnology (APOP) has developed a breakthrough technology and line of products, for the functional selection of cells. The Company is in clinical development of its lead product – the ApoGraft™ - improving Bone Marrow Transplantations (BMT) outcome.The Company’s technology aims to improve the robustness, safety and efficacy of a variety of cell and gene therapies and therefore can be used by researchers, clinical community and pharma companies in a wide variety of applications including next generation CAR-T, NK, MSC and gene therapies.  During human clinical trials, the Company has previously disclosed that interim data has unequivocally met safety and tolerability end point, further validating ApoGraft.Forward Looking Statements                      This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company’s ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC.Contact Cellect Biotechnology Ltd. Eyal Leibovitz, Chief Financial Officer www.cellect.co +972-9-974-1444OrEVC Group LLC   Michael Polyviou (732) 933-2754 mpolyviou@evcgroup.com